Virometix

Switzerland
Schlieren, Zurich, Switzerland, CH-8952

Company profile

Virometix company profile

Virometix is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges. Rational molecular design, chemical synthesis and Virometix' proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$1M-$10M
Founded
2009-01-01, Year

Headquarters

Postal code
CH-8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
7
Total equity funding
$29.3M
Last funding
Undisclosed / $15M / 2025-11-13
Last equity funding
Undisclosed / $15M
Investors
2
Lead investors
1
Articles
29

Founders and investors

Lead investors

Venture Kick

Investors

Harry WeltenVenture Kick